1438-66-0
Chemical Structure
Larixol
Synonym(s): (+)-Larixol
- CAS No.: 1438-66-0
- Formula:C20H34O2
- Molecular Weight:306.48
IUPAC Name: (1S,4S,4aR,8aS)-4-((S)-3-hydroxy-3-methylpent-4-en-1-yl)-4a,8,8-trimethyl-3-methylenedecahydronaphthalen-1-ol
InChIKey: CLGDBTZPPRVUII-HROONELDSA-N
SMILES: C[C@]12[C@@](C(C)(CCC2)C)([H])[C@H](CC([C@@H]1CC[C@](C)(O)C=C)=C)O
Biological Activity: Larixol is an fMLP inhibitor and also inhibits Src kinase, ERK1/2, p38 and AKT phosphorylation signals in immune regulation. Larixol can interfere with the interaction between the βγ subunit of the fMLP receptor Gi protein and its downstream molecules, thereby inhibiting fMLP-induced respiratory burst. Larixol inhibits fMLP (0.1 μM)-induced superoxide anion production (IC50: 1.98 μM), cathepsin G release (IC50: 2.76 μM), and chemotaxis. Larixol improves neutrophil hyperactivation and reduces inflammation or tissue damage. A series of Larixol derivatives were found to have inhibitory effects on FSGS-related TRPC6 functional mutants[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Larixol | 95.52% | Larixol is an fMLP inhibitor and also inhibits Src kinase, ERK1/2, p38 and AKT phosphorylation signals in immune regulation. Larixol can interfere with the interaction between the βγ subunit of the fMLP receptor Gi protein and its downstream molecules, thereby inhibiting fMLP-induced respiratory burst. Larixol inhibits fMLP (0.1 μM)-induced superoxide anion production (IC50: 1.98 μM), cathepsin G release (IC50: 2.76 μM), and chemotaxis. Larixol improves neutrophil hyperactivation and reduces inflammation or tissue damage. A series of Larixol derivatives were found to have inhibitory effects on FSGS-related TRPC6 functional mutants. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Liao HR, et al. Larixol inhibits fMLP-induced superoxide anion production and chemotaxis by targeting the βγ subunit of Gi-protein of fMLP receptor in human neutrophils. Biochem Pharmacol. 2022 Jul;201:115091. [Content Brief]
- [2]. Urban N, et al. Pharmacological inhibition of focal segmental glomerulosclerosis-related, gain of function mutants of TRPC6 channels by semi-synthetic derivatives of larixol. Br J Pharmacol. 2017 Nov;174(22):4099-4122. [Content Brief]
Keywords
